Respondent
Ascent Health Services, LLCGroup purchasing organization named in the FTC insulin administrative complaint record.
Source-specific evidence
The FTC administrative complaint names affiliated GPO Ascent Health Services as a respondent.
Official record dossierLitigationComplaint
FTC files administrative complaint against the three largest PBMs
The FTC brought an administrative action alleging anticompetitive and unfair rebating and formulary practices involving Caremark, Express Scripts, OptumRx, and affiliated GPOs.
Adds alleged conduct and patient-harm context to the PBM profile. The allegations remain distinct from the descriptive concentration evidence and do not supply missing individual shares.
Official recordFTC files administrative complaint against the three largest PBMsComplaint / Federal Trade Commission / 1 market
- Record identityevt-pbm-insulin-complaint-2024Sep 20, 2024
- Official scopeComplaintFederal Trade Commission
- Market scope1 linked contextSeparately bounded profiles
- Permitted inferenceChronology + contextNo automatic causal claim
Exact named-organization edges
Who this official record names
Respondent
Caremark Rx, LLCPharmacy benefit manager named in FTC study and administrative complaint records.
Source-specific evidence
The FTC administrative complaint names Caremark Rx as a respondent.
Respondent
Emisar Pharma Services LLCGroup purchasing organization named in the FTC insulin administrative complaint record.
Source-specific evidence
The FTC administrative complaint names affiliated GPO Emisar Pharma Services as a respondent.
Respondent
Express Scripts, Inc.Pharmacy benefit manager named in FTC study and administrative complaint records.
Source-specific evidence
The FTC administrative complaint names Express Scripts as a respondent.
Respondent
OptumRx, Inc.Pharmacy benefit manager named in FTC study and administrative complaint records.
Source-specific evidence
The FTC administrative complaint names OptumRx as a respondent.
Respondent
Zinc Health Services, LLCGroup purchasing organization named in the FTC insulin administrative complaint record.
Source-specific evidence
The FTC administrative complaint names affiliated GPO Zinc Health Services as a respondent.
A relationship means an official source names the organization in connection with the dated record. It does not by itself establish liability, market power, ownership, control, or that the organization participates in every market linked to that record.
Descriptive economic context
Public HHI evidence around this date
Each row searches one linked market profile for strict pre-event, same-year, and strict post-event observations. Missing anchors remain part of the result.
0Paired
0One-sided
1Unavailable
- Strict pre
- Unavailable
- No earlier HHI
- Event year
- Unavailable
- No same-year HHI
- Strict post
- Unavailable
- No later HHI
- Pre-post change
- Not available
- Pair not available
Before/after HHI differences are descriptive comparisons between discrete public releases. They do not estimate the causal effect of the policy event.
Bounded market context
Markets linked to this record
United States / Health care
HHI unavailablePBMs
Pharmacy benefit management services profile based on FTC public findings. The FTC reports top-three and top-six aggregate shares but not enough individual PBM market shares in the public press-release record to compute HHI.
A linked market identifies the observatory context assigned to this record. It is not necessarily the relevant antitrust market alleged or adjudicated in the official matter.
Source custody
Official source behind the record
Federal Trade Commission / agency report
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
FTC administrative complaint record concerning alleged rebating and formulary practices by the three largest PBMs and affiliated GPOs.
Accessed Jul 17, 2026. Federal Trade Commission, FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices, September 20 2024.
License note: Public federal government record
Nearby observatory chronology
Other records sharing these market contexts
Explicit proceeding membership / record 1 of 3
FTC insulin-rebate administrative matter
Open the declared chronology before using market-linked nearby records as broader context.
Jul 14, 2026
RemedyFeb 4, 2026
RemedyFederal Trade Commission
FTC announces proposed consent agreement with Express ScriptsShared context: PBMs
Jul 9, 2024
MonitoringFederal Trade Commission
FTC releases interim staff report on prescription drug middlemenShared context: PBMs
This chronology is generated from shared observatory market links. It does not assert that the records concern the same matter, conduct, parties, or theory of harm.
Reproducible record packet
Reuse this record and its joins
Filtered routes preserve the exact event ID across the official record, named-organization edges, descriptive market windows, and linked market profiles.
- Event ID
- evt-pbm-insulin-complaint-2024
- Profile slug
- pbm-insulin-complaint-2024
- Docket
- Docket No. 9437
- License
- CC BY 4.0
Official-record interpretation boundary
A record dossier preserves what one dated official source says and the observatory context linked to it. It does not convert allegations into findings, findings into economy-wide conclusions, or nearby market indicators into causal effects.
A linked market identifies the observatory context assigned to this record. It is not necessarily the relevant antitrust market alleged or adjudicated in the official matter.